 |
市场调查报告书
商品编码
1190809
眼保健品市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)Eye Health Supplement Market- Growth, Trends, and Forecasts (2023 - 2028) |
||||||
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
在预测期内（2022 年至 2027 年），眼保健品市场预计将以 6.5% 的复合年增长率增长。
自世界卫生组织于 2020 年 3 月 11 日宣布 2019 年冠状病毒病（或 COVID-19）为大流行病以来，世界上许多国家/地区都实施了全国封锁。 为最大程度地降低传播 COVID-19 的风险，暂停了常规医疗保健服务，并建议患者除非绝对必要，否则不要去医院就诊。 这些趋势严重扰乱了眼科保健服务和患者护理的提供。 根据 2020 年 10 月发表的一项题为“COVID-19 大流行对眼科服务的影响：我们准备好迎接善后了吗？”的研究，眼科是最繁忙、门诊病人最多的专科之一。它代表了大约 750 万次门诊预约等等英国每年有超过 500,000 例外科手术。 最近的大流行封锁取消了数千次眼科门诊就诊和手术，可能对患者的视力造成永久性和重大损害。 另据报导，COVID-19 大流行对印度的眼科服务产生了重大影响，临床和外科服务下降了 95% 以上。 就诊人数的下降影响了眼保健品在患者群体中的应用。 然而，随着远程医疗和虚拟护理实践的开展，对眼保健品的需求在不久的将来可能会激增至大流行前的水平。 因此，在大流行初期，这种选择性对市场增长产生了负面影响，例如取消了例行的眼科检查。 然而，预计该市场在未来几年将获得更大的吸引力。
推动眼保健品市场增长的主要因素是全球眼病患病率上升。 由于不受控制的糖尿病会导致糖尿病性视网膜病变，因此预计研究目标市场将受到全球老年人口和糖尿病不断增加的推动。 根据联合国《2019年世界人口老龄化报告》，2019年全球65岁及以上人口为7.03亿，预计到2050年将翻一番，达到15亿。 根据世界卫生组织2021年的统计，全球至少有22亿人患有近视或远视。 对于这些人中至少有 10 亿人（将近一半）来说，视力丧失本可以得到预防或尚未得到解决。 此外，根据干眼症目录 2022 年的统计数据，现在有 16 至 4900 万美国人患有干眼症。 这占人口的 5-15%。 眼病患病率的增加可能会刺激患者群体对眼保健品的需求。
此外，创新产品的推出也在推动市场的增长。 例如，2021 年 7 月，Healthy Directions 宣布推出 Vision Essentials ULTRA，这是其广受欢迎且有效的 Whitaker Nutrition 系列的突破性日常视力补充剂。 同样，2021 年 5 月，PharmaLinea 以消费者友好的形式推出了一系列预防性眼保健品。 该决定是由于大流行导致屏幕时间增加和眼睛健康问题增加。 同样在 2021 年 2 月，Univer Inc.宣布与 Health Thru Nutrition 合作推出 Health Thru Nutrition 辣椒红素补充剂，包括 CapsiClear。
因此，由于上述因素，预计所研究的市场将在预测期内得到推动。 然而，与眼保健品相关的高成本可能会阻碍市场增长。
主要市场趋势
预计抗氧化剂板块在预测期内将呈现更好的增长
老年人口的增加、糖尿病患病率的上升、年龄相关性黄斑变性 (AMD) 等眼病、白内障和糖尿病性视网膜病变预计将推动北美研究市场的增长。 此外，黄斑变性通常称为年龄相关性黄斑变性 (AMD)，是一种与年龄相关的眼病，会导致锐利和中心视力丧失。 根据 2021 年黄斑变性研究，黄斑变性是 60 岁以上美国人视力丧失的主要原因。 在美国，多达 1100 万人患有某种形式的年龄相关性黄斑变性。 到 2050 年，这一数字预计将翻一番，达到 2200 万。 年龄是年龄相关性黄斑变性的主要危险因素。 据说 50-59 岁的人患晚期老年性黄斑变性的风险增加到 2%，75 岁及以上的人增加近 30%。
此外，该地区主要参与者的集中和新产品发布的增加正在推动所研究市场的增长。 例如，2019 年 7 月，博士伦在美国推出了 Ocuvite Eye Performance，这是一种具有七种关键营养素的眼部维生素，可强化黄斑部并保护眼睛免受压力。 同样，主要参与者正在实施各种战略，例如研发投资、合作和收购，以扩大其在该地区的产品组合。 其中之一是与 ZeaVision LLC (iPromise) 的合作协议。 (IPromise) 于 2019 年 11 月与波士顿红袜队合作，成为整个 2020 年的官方 iVitamin 品牌。
2021 年 12 月，得克萨斯州营养补充剂公司 TJ Nutrition 根据遗传病研究人员的临床研究创造了一种独一无二的专利补充剂，将在减少炎症的同时增加泪液生成。宣布推出一种科学的经过验证的突破性专利化合物 Parasim Plus Eyes。 Parasim Plus Eyes 可增强泪腺和迷走神经的功能，从而改善神经系统并同时改善全身和眼部健康。
因此，由于上述因素，北美有望在预测期内对眼保健品市场做出重大贡献。
北美在眼部保健品市场占据主导地位，预计在预测期内将经历巨大增长
老年人口的增加、糖尿病患病率的上升、年龄相关性黄斑变性 (AMD) 等眼病、白内障和糖尿病性视网膜病变预计将推动北美研究市场的增长。 此外，黄斑变性通常称为年龄相关性黄斑变性 (AMD)，是一种与年龄相关的眼病，会导致锐利和中心视力丧失。 根据 2021 年黄斑变性研究，黄斑变性是 60 岁以上美国人视力丧失的主要原因。 在美国，多达 1100 万人患有某种形式的年龄相关性黄斑变性。 到 2050 年，这一数字预计将翻一番，达到 2200 万。 年龄是年龄相关性黄斑变性的主要危险因素。 据说 50-59 岁的人患晚期老年性黄斑变性的风险增加到 2%，75 岁及以上的人增加近 30%。
此外，该地区主要参与者的集中和新产品发布的增加正在推动所研究市场的增长。 例如，2019 年 7 月，博士伦在美国推出了 Ocuvite Eye Performance，这是一种具有七种关键营养素的眼部维生素，可强化黄斑部并保护眼睛免受压力。 同样，主要参与者正在实施各种战略，例如研发投资、合作和收购，以扩大其在该地区的产品组合。 其中之一是 ZeaVision LLC. (IPromise) 于 2019 年 11 月与波士顿红袜队合作，成为整个 2020 年的官方 iVitamin 品牌。
2021 年 12 月，得克萨斯州营养补充剂公司 TJ Nutrition 根据遗传病研究人员的临床研究创造了一种独一无二的专利补充剂，将在减少炎症的同时增加泪液生成。宣布推出一种科学的经过验证的突破性专利化合物 Parasim Plus Eyes。 Parasim Plus Eyes 可增强泪腺和迷走神经的功能，从而改善神经系统并同时改善全身和眼部健康。
由于上述原因，预计在预测期内，北美将对眼保健品市场做出重大贡献。
竞争格局
眼睛保健品市场竞争激烈，由许多主导市场的大型企业组成。 此外，许多中小企业也积极参与研发活动，并希望进军研究市场，这将在预测期内带来爆炸式增长。 研究市场的主要参与者包括 Bausch & Lomb, Incorporated、ZeaVision, LLC、Amway International、Akorn Consumer Health、Vitabiotics Ltd、Nature's Bounty, Co. 等。
其他福利。
- Excel 格式的市场预测 (ME) 表
- 三个月的分析师支持
内容
第1章介绍
- 研究假设和市场定义
- 调查范围
第2章研究方法论
第 3 章执行摘要
第4章市场动态
- 市场概览
- 市场驱动因素
- 眼病患病率增加
- 老龄化人口的增加和糖尿病患病率的增加
- 在日常生活中更多地使用屏幕和显示器
- 市场製约因素
- 眼保健品费用高
- 波特的五力分析
- 新进入者的威胁
- 买方/消费者议价能力
- 供应商的议价能力
- 替代品的威胁
- 竞争公司之间的敌对关係
第 5 章市场细分
- 按类型
- 抗氧化剂
- 脂肪酸
- 抗炎补充剂
- 神经保护补充剂
- 其他
- 根据指示
- 年龄相关性黄斑变性 (AMD)
- 白内障
- 干眼症
- 糖尿病视网膜病变
- 其他
- 按地区
- 北美
- 美国
- 加拿大
- 墨西哥
- 欧洲
- 德国
- 英国
- 法国
- 意大利
- 西班牙
- 其他欧洲地区
- 亚太地区
- 中国
- 日本
- 印度
- 澳大利亚
- 韩国
- 其他亚太地区
- 中东和非洲
- 海湾合作委员会
- 南非
- 其他中东和非洲地区
- 南美洲地区
- 巴西
- 阿根廷
- 其他南美洲
- 北美
第6章竞争格局
- 公司简介
- Bausch & Lomb Incorporated
- Pfizer, Inc.
- Amway International
- Akorn Consumer Health
- Vitabiotics Ltd
- ZeaVision, LLC
- Nature's Bounty Co.
- Nutrivein
- Kemin Industries, Inc.
- EyeScience Labs
- Zenith Labs
- Performance Lab Ltd.
- Nuzena LLC
第7章 市场机会与今后动向
The eye health supplement market is projected to register a CAGR of 6.5% during the forecast period (2022-2027).
Many countries around the world have imposed nationwide lockdowns since the World Health Organization declared Coronavirus Disease 2019 (or COVID-19) to be a pandemic on March 11, 2020. Routine healthcare services were canceled, and patients were advised to avoid hospital visits unless critically necessary, to minimize the risk of COVID-19 transmission. These trends led to significant disruption to the provision of eye healthcare services and patient care. As per the study published in October 2020, titled "The impact of COVID-19 pandemic on ophthalmology services: are we ready for the aftermath?", ophthalmology represented one of the busiest and most heavily outpatient-oriented specialties, with approximately 7.5 million outpatient appointments and more than 500,000 surgical procedures in United Kingdom each year. The recent pandemic lockdown resulted in the cancellation of thousands of ophthalmic clinical visits and surgeries, which could potentially lead to permanent and significant harm to patients' vision. The study also reported a significant impact of the COVID-19 pandemic on the ophthalmology service in India, with clinical and surgical services being reduced by >95%. Such a decrease in patient visits impacted the adoption of eye health supplements among the patient population. However, owing to teleconsultations and virtual care practices, the demand for eye health supplements is likely to soar to its pre-pandemic levels in the near future. Thus, in view of its elective nature, the cancellation of routine ophthalmic visits in the initial pandemic phase had an adverse impact on the market's growth. However, the market is anticipated to gain traction over the coming years.
The major drivers propelling the growth of the eye health supplement market are the increasing prevalence of eye disorders globally. The studied market is expected to be driven by the growing global geriatric population and diabetes, as uncontrolled diabetes leads to diabetic retinopathy. According to the United Nations, World Population Ageing 2019, there were 703 million people aged 65 years or over in the world in 2019, and the number is projected to double to 1.5 billion in 2050. As per the World Health Organization Statistics of 2021, globally, at least 2.2 billion people have a near-or distance vision impairment. In at least 1 billion, or almost half of these cases, vision impairment could have been prevented or has yet to be addressed. Furthermore, as per the Dry Eye Directory's statistics for 2022, between 16 million and 49 million Americans currently have dry eyes. This is between 5-15% of the population. The increasing prevalence of eye disorders is likely to impel the demand for eye health supplements among the patient population.
Besides, the launch of innovative products is also boosting the market's growth. For instance, in July 2021, Healthy Directions announced the introduction of Vision Essentials ULTRA, a breakthrough one-a-day vision supplement in its highly popular and efficacious Whitaker Nutrition line. Likewise, in May 2021, PharmaLinea launched a line of preventative eye health supplements in consumer-friendly formats. The decision came as a result of the pandemic, which has increased screen time and contributed to an increase in eye health concerns. Also, in February 2021, Unibar Corporation announced a partnership with Health Thru Nutrition and the availability of the Health Thru Nutrition Capsanthin supplement containing CapsiClear.
Thus, owing to the aforementioned factors, the studied market is expected to propel over the forecast period. However, higher costs associated with eye health supplement products are likely to impede market growth.
Key Market Trends
Antioxidant Segment is Expected to Show Better Growth over the Forecast Period
The rise in the geriatric population, the increasing prevalence of diabetes, and eye disorders such as age-related macular degeneration (AMD), cataract, diabetic retinopathy, and other eye disorders are expected to drive the growth of the studied market in North America. Besides, macular degeneration, often called age-related macular degeneration (AMD), is an eye disorder associated with aging and results in damaged sharp and central vision. As per the Macular Degeneration Research 2021, macular degeneration is a leading cause of vision loss in Americans aged 60 years of age and older. As many as 11 million people in United States have some form of age-related macular degeneration. This number is expected to double to nearly 22 million by 2050. Age is a prominent risk factor for age-related macular degeneration. The risk of getting advanced age-related macular degeneration increases from 2% for those ages 50-59 to nearly 30% for those over the age of 75.
Additionally, the increasing concentration of major players and new product launches in the region adds to the growth of the studied market. For instance, in July 2019, Bausch + Lomb launched Ocuvite Eye Performance, an eye vitamin supplement formulated with seven vital nutrients that help strengthen the macula and protect the eye from stress in United States. Likewise, the major players are evolving various strategies, such as investment in research and development, collaborations, and acquisitions, for the expansion of their product portfolios in the region. One such collaboration was the partnership agreement of ZeaVision LLC. (EyePromise) with the Boston Red Sox in November 2019 as an official eye vitamin brand throughout 2020.
In December 2021, TJ Nutrition, a Texas nutraceutical company that creates one-of-a-kind, patented supplements based on genetic disease investigators' clinical research, announced the launch of Parasym Plus Eyes, a revolutionary and patented compound scientifically proven to increase tear production while reducing inflammation. By enhancing both lacrimal and vagus nerve function, Parasym Plus Eyes improves both systemic and ocular health neurologically and concurrently.
Thus, in view of the aforementioned factors, North America is expected to contribute significantly to the eye health supplement market over the forecast period.
North America has a Dominant Share in Eye Health Supplements Market and is Anticipated to Grow Tremendously over the Forecast Period
The rise in the geriatric population, the increasing prevalence of diabetes, and eye disorders such as age-related macular degeneration (AMD), cataract, diabetic retinopathy, and other eye disorders are expected to drive the growth of the studied market in North America. Besides, macular degeneration, often called age-related macular degeneration (AMD), is an eye disorder associated with aging and results in damaged sharp and central vision. As per the Macular Degeneration Research 2021, macular degeneration is a leading cause of vision loss in Americans aged 60 years of age and older. As many as 11 million people in United States have some form of age-related macular degeneration. This number is expected to double to nearly 22 million by 2050. Age is a prominent risk factor for age-related macular degeneration. The risk of getting advanced age-related macular degeneration increases from 2% for those ages 50-59 to nearly 30% for those over the age of 75.
Additionally, the increasing concentration of major players and new product launches in the region adds to the growth of the studied market. For instance, in July 2019, Bausch + Lomb launched Ocuvite Eye Performance, an eye vitamin supplement formulated with seven vital nutrients that help strengthen the macula and protect the eye from stress in United States. Likewise, the major players are evolving various strategies, such as investment in research and development, collaborations, and acquisitions, for the expansion of their product portfolios in the region. One such collaboration was the partnership agreement of ZeaVision LLC. (EyePromise) with the Boston Red Sox in November 2019 as an official eye vitamin brand throughout 2020.
In December 2021, TJ Nutrition, a Texas nutraceutical company that creates one-of-a-kind, patented supplements based on genetic disease investigators' clinical research, announced the launch of Parasym Plus Eyes, a revolutionary and patented compound scientifically proven to increase tear production while reducing inflammation. By enhancing both lacrimal and vagus nerve function, Parasym Plus Eyes improves both systemic and ocular health neurologically and concurrently.
Thus, in view of the aforementioned factors, North America is expected to contribute significantly to the eye health supplement market over the forecast period.
Competitive Landscape
The Eye Health Supplement market is highly competitive and consists of many major players that dominate the market. Also, many small and medium-sized companies are also actively involved in R&D activities and trying to set foot in the studied market, thereby leading to an impactable growth over the forecast period. The major players in the studied market are Bausch & Lomb, Incorporated, ZeaVision, LLC., Amway International, Akorn Consumer Health, Vitabiotics Ltd, and Nature's Bounty, Co., among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Increasing Prevalence of Eye disorders
- 4.2.2 Growing Geriatric Population and High Incidence of Diabetes
- 4.2.3 Increased Usage of Screens and Monitors in Daily Routine
- 4.3 Market Restraints
- 4.3.1 High Cost of Eye Care Supplements
- 4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 By Type
- 5.1.1 Antioxidants
- 5.1.2 Fatty Acids
- 5.1.3 Anti-inflammatory Supplements
- 5.1.4 Neuro-Protective Supplements
- 5.1.5 Others
- 5.2 By Indication
- 5.2.1 Age-Related Macular Degeneration (AMD)
- 5.2.2 Cataract
- 5.2.3 Dry Eye Syndrome
- 5.2.4 Diabetic Retinopathy
- 5.2.5 Others
- 5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle-East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle-East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
- 5.3.1 North America
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 Bausch & Lomb Incorporated
- 6.1.2 Pfizer, Inc.
- 6.1.3 Amway International
- 6.1.4 Akorn Consumer Health
- 6.1.5 Vitabiotics Ltd
- 6.1.6 ZeaVision, LLC
- 6.1.7 Nature's Bounty Co.
- 6.1.8 Nutrivein
- 6.1.9 Kemin Industries, Inc.
- 6.1.10 EyeScience Labs
- 6.1.11 Zenith Labs
- 6.1.12 Performance Lab Ltd.
- 6.1.13 Nuzena LLC
